RxDoctor Payments Data

Joann Chang, MD

Ophthalmology · Lancaster, MANPI 1730359100

Payments from drug & device makers

$39,708in general payments, 2019–2025

Across 133 payments — averaging $298.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$35K
  • Alcon$1K
  • Rxsight Inc$652
  • Oyster Point Pharma, Inc.$494
  • Sun Pharmaceutical Industries Inc.$476
  • Tarsus Pharmaceuticals, Inc.$295
  • plus $2K from 15 others

What the payments were for

  • Speaking & faculty fees$31,03878%
  • Travel & lodging$2,3016%
  • Food & beverage$6,35116%
  • Education$180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,708 in reported general payments places this provider in the 90th percentile of 653 ophthalmology providers in Massachusetts.

See all ophthalmology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$440,385
Medicare patients
742
Services billed
3,190

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj12$336,081
RestasisCyclosporine199$258,493
XiidraLifitegrast52$94,046
MieboPerfluorohexyloctane/Pf83$61,905
TyrvayaVarenicline Tartrate69$49,670
Cyclosporine55$32,940
Bromfenac Sodium144$23,224
Prednisolone Acetate679$21,340
IlevroNepafenac43$15,999
LotemaxLoteprednol Etabonate41$14,707
BromsiteBromfenac Sodium39$10,997
CequaCyclosporine12$9,025
Loteprednol Etabonate37$6,947
Ketorolac Tromethamine275$4,777
Fluorometholone44$3,310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$120$336,08112 claims
AbbVieRestasis$34,822$258,493199 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$270$155,951135 claims
Oyster Point Pharma, Inc.Tyrvaya$494$49,67069 claims
Sun Pharmaceutical Industries Inc.Bromsite, Cequa$476$20,02251 claims
NovartisIlevro$143$15,99943 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 653 ophthalmology providers in Massachusetts.

Other ophthalmology in Lancaster

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →